+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Insight: Prostate Cancer: Competition intensifies in race to the top

  • ID: 2573641
  • Report
  • June 2013
  • Region: Global
  • 140 Pages
  • FirstWord Publishing
1 of 3
The Prostate Cancer market has seen a number of progressive changes in recent years. The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi (enzalutamide) has reinvigorated the post-chemo treatment segment, while launch of the first cancer vaccine Provenge (sipuleucel-T; Dendreon) and Zytiga's expanded approval had finally given new options in the pre-chemo setting.

With similar efficacy and tolerability profiles, Zytiga and Xtandi are currently vying for first-line status in both the post and pre-chemo disease settings as both drugs are set to generate blockbusting revenues despite clinical and health payer concerns about the high cost of treatment. The recentaddition of Xofigo, the first licensed alpha-emitter in prostate cancer, also represents a paradigm shift in treatment.

Competition in the major segments of prostate cancer are set to intensify, with new hormone drugs, radiation therapy, chemotherapy add-ons and immunotherapies in the pipeline. The high level of unmet need, premium pricing and patient population growth continue to make the market an attractive proposition for ‘would be' developers. There remains a significant opportunity to generate substantial revenues in this highly-segmented disease, in the therapeutic segment and alsoin advanced diagnostics.

Therapy Trends: Prostate Cancer' is compiled from exclusive, in-depth interviews with the world's leading Key Opinion Leaders in Prostate Cancer. It identifies and analyses the major factors, advances and trends currently influencing the Prostate Cancer treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future Prostate Cancer management.

The KOLs for this Therapy Trends report were selected based on their level of engagement and influence within the Prostate Cancer disease area, and their scientific standing and clinical experience. The unique KOL scoring system identifies those thought-leaders with the greatest insight into how Prostate Cancer clinical research will shape the future market.

This report examines the most prominent insights gained from the field's key opinion leaders. The results of the research and analysis will help you to:

- Comprehend the current trends driving and shaping the global prostate cancer market
- Understand the future landscape and how new classes will fit into the treatment algorithm
- Compare and contrast the clinical profile of Johnson & Johnson's Zytiga and Medivation/Astellas's Xtandi and assess their competitive strengths and weaknesses
- Assess the impact of Xofigo's arrival onto the market
- Assess the commercial and clinical potential of the pipeline hormone drugs, radiation therapy, chemotherapy add-ons and next generation immunotherapy
- Appreciate KOL calls for diagnostic biomarkers and understand the commercial threat and opportunity such products present.
- Develop planning strategies based on KOL insight
- Identify critical areas of unmet clinical need and opportunities for better disease management
- Understand how the treatment paradigm will evolve in the future
- Evaluate the performance of companies with the most robust new product pipelines
- Recognise the key factors KOLs predict will drive future treatment trends

The Prostate Cancer market is one of the most dynamic markets in Pharma, and with the medical unmet need, long treatment course and growing population size, the disease is set to deliver a number of blockbusting therapies. Although treatment will not be revolutionised by the new therapies, there will be evolution with better, more efficacious therapies entering the defined disease segments. KOLs from North America and Europe provide answers to some critical questions regarding the global Prostate Cancer market, including:

- What pro's and con's do KOLs identify for Zytiga and Xtandi and what influences clinical choice?
- How will pricing affect Xofigo's uptake?
- How might new therapies impact on current first-line chemo treatments?
- What are the current unmet needs and major challenges in prostate cancer treatment?
- What are the most promising late-stage classes in development?
- Which therapy are KOLs eagerly awaiting?
- How will the new therapies be positioned against each other in each of the disease segments?
- In what ways could biomarkers improve future Prostate Cancer disease management and what impact could this have on prescribing?
- How will treatment of Prostate Cancer look in the future?
- How do KOLs think the pricing environment is shaping the uptake of new Prostate Cancer treatments?
- What clinical research trends do KOLs predict for future Prostate Cancer therapies?
Note: Product cover images may vary from those shown
2 of 3
1. Executive summary

2. Introduction

3. Methodology

4. Current Prostate Cancer marketplace
- Prostate cancer overview
- Etiology
- Symptoms
- Diagnosis
- Prostate cancer treatment
- Current treatment landscape
- Reimbursement of key prostate cancer brands
- Unmet needs in Prostate Cancer

5. Current therapies
- Androgen inhibitors overview
-- Zytiga (abiraterone acetate; Johnson & Johnson)
-- Xtandi (enzalutamide; Medivation/Astellas)
- Cytotoxic therapies overview
-- Taxotere (docetaxel; Sanofi)
-- Jevtana (cabazitaxel; Sanofi)
- Hormonal therapy overview
-- Lupron (leuprolide acetate; Takeda/Abbott)
-- Casodex (bicalutamide; AstraZeneca)
-- Nilandron (nilutamide; Sanofi/Astellas)
-- Eulexin (flutamide; Merck & Co./Nippon Kayaku)
- Other therapies overview
-- Xofigo (radium-223 dichloride; Algeta/Bayer)
-- Provenge (sipuleucel-T; Dendreon)
-- Xgeva (denosumab; Amgen)
- Current treatment algorithm

6. Pipeline therapies
- Tasquinimod (Active Biotech/Ipsen)
- Cabozantinib (Exelixis)
- Sprycel (dasatinib; Bristol-Myers Squibb)
- TAK-700 (Orteronel; Takeda/ Millennium)
- Prostvac (Bavarian Nordic)
- Alpharadin (radium-233 dichloride; Algeta/Bayer)
- Yervoy (ipilimumab; Bristol-Myers Squibb)
-- Future treatment algorithm

7. Future developments in Prostate Cancer
- Clinical trials to be redesigned with new drugs entering market
- Development of biomarkers is on the horizon
- Novel interesting targets to still target androgen
- Over treatment of disease will be phased out

8. Appendix
- KOL biographies
Note: Product cover images may vary from those shown
3 of 3
Adroll
adroll